Cleo’s Chief Scientific Officer Dr Andrew Stephens and Head of Corporate Development Dayna Louca recently spoke at the JMM Opera House Investor Lunch on how their breakthrough CXCL10 biomarker platform could address one of medicine’s toughest challenges, the early detection of ovarian cancer.

Watch the Q&A with Head of Corporate Development Dayna Louca.

Cleo Diagnostics Chief Scientific Officer, Dr Andrew Stephens, joins Andrew Geoghegan of ausbiz to discuss the importance of the partnership with the University College London to access 2000 UKCTOCS biobank samples.